Actively Recruiting
Study Comparing PF-08634404 Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Women With Advanced or Recurrent Mismatch Repair-Proficient Endometrial Cancer
Led by Pfizer · Updated on 2026-10-30
600
Participants Needed
54
Research Sites
86 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying advanced or recurrent endometrial cancer that has a functioning mismatch repair system, called pMMR. This cancer type is harder for the immune system to attack. The study compares a new medicine, PF-08634404, combined with chemotherapy, against pembrolizumab plus chemotherapy. It aims to see if the new combination improves outcomes for women with this type of endometrial cancer. Participants receive intravenous infusions of their assigned treatment in cycles. One group receives PF-08634404 plus chemotherapy followed by PF-08634404 alone for up to 2 years, while the other group receives pembrolizumab plus chemotherapy followed by pembrolizumab alone for up to 2 years. About 600 adult women will be randomly assigned to these groups in an open-label design where both patients and doctors know the treatment. Participants attend regular visits for treatment and health assessments. Cancer response is checked every 9 weeks for about 2 years, then every 12 weeks afterward. Follow-up continues every 12 weeks by phone, in person, or health record review. Researchers measure progression-free survival, overall survival, treatment responses, safety, quality of life, and other health outcomes during and after treatment.
CONDITIONS
Brief Title
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here